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The NLRP3 inflammasome is a component of the inflammatory process and its 
aberrant activation is pathogenic in inherited disorders such as the cryopyrin 
associated periodic syndromes (CAPS) and complex diseases such as multiple 
sclerosis, type 2 diabetes and atherosclerosis. We describe the development of 
MCC950, a potent, selective, small molecule inhibitor of NLRP3. MCC950 blocks 
canonical and non-canonical NLRP3 activation at nanomolar concentrations. 
MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. 
MCC950 reduces Interleukin-1β (IL-1β) production in vivo and attenuates the 
severity of experimental autoimmune encephalomyelitis (EAE), a disease model 
of multiple sclerosis. Furthermore, MCC950 treatment rescues neonatal lethality 
in a mouse model of CAPS and is active in ex vivo samples from individuals with 
Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-
associated syndromes, including autoinflammatory and autoimmune 
diseases,and a tool for the further study of the NLRP3 inflammasome in human 
health and disease. 
  
Introduction  
The NOD-like receptor family (NLR) protein NLRP3 is an intracellular signalling 
molecule that senses many pathogen-, environmental- and host-derived factors1. 
Upon activation NLRP3 binds to apoptosis associated speck-like protein 
containing a CARD (ASC). ASC in turn interacts with the cysteine protease 
caspase-1, forming a complex termed the inflammasome. This results in the 
activation of caspase-1, which cleaves the pro-inflammatory cytokines IL-1β and 
IL-18 to their active forms and mediates a type of inflammatory cell death known 
as pyroptosis2. Other intracellular pattern recognition receptors (PRRs) are also 
capable of forming inflammasomes. These include other NLR family members 
such as NLRP1 and NLRC4 and non-NLR PRRs such as the double-stranded 
DNA (dsDNA) sensors absent in melanoma 2 (AIM2) and interferon, gamma 
inducible protein 16 (IFI16)3. NLRP3-dependent IL-1β processing can also be 
activated by an indirect, non-canonical pathway downstream of caspase-114. 
The inherited CAPS Muckle-Wells syndrome (MWS), familial cold 
autoinflammatory syndrome (FCAS) and neonatal onset multi-system 
inflammatory disease (NOMID) are caused by gain of function mutations in 
NLRP3, thus defining NLRP3 as a critical component of the inflammatory 
process5. NLRP3 has also been implicated in the pathogenesis of a number of 
complex diseases, notably metabolic disorders such as type 2 diabetes, 
atherosclerosis, obesity and gout6. A role for NLRP3 in diseases of the central 
nervous system is emerging, while lung diseases have also been shown to be 
influenced by NLRP37. Furthermore, NLRP3 plays a role in the development of 
liver disease8, kidney disease9 and aging10. Many of these associations were 
defined using Nlrp3–/– mice but there have also been insights into the specific 
activation of NLRP3 in these diseases. In type 2 diabetes the deposition of islet 
amyloid polypeptide (IAPP) in the pancreas activates NLRP3 and IL-1β signalling 
resulting in β-cell death and inflammation11. 
Current treatments for NLRP3 related diseases include biologic agents that 
target IL-1. These are the recombinant IL-1 receptor antagonist Anakinra, the 
neutralizing IL-1β antibody Canakinumab and the soluble decoy IL-1 receptor 
Rilonacept. This has proven successful in the treatment of CAPS and these 
biologic agents have been subject to clinical trials for other IL-1β associated 
diseases12. Several small molecules have been shown to inhibit the NLRP3 
inflammasome. Glyburide inhibits IL-1β production at micromolar concentrations 
in response to NLRP3 but not NLRC4 or NLRP1 activation13. We previously 
described a small molecule capable of inhibiting both NLRP3 and AIM2 at 
micromolar concentrations. This molecule was initially incorrectly termed CRID3 
but was in fact a Bayer compound that is a cysteinyl leukotriene receptor 
antagonist14. Other purported NLRP3 inhibitors include parthenolide15, 3,4-
methylenedioxy-β-nitrostyrene (MNB)16 and dimethyl sulfoxide (DMSO)17, 
although these agents have limited potency and are non-specific. 
In 2001 a number of diarylsulfonylurea-containing compounds were identified as 
novel IL-1β processing inhibitors18. In this study we have investigated one of 
these we have termed MCC95019. The synthesis and chemical structure of 
MCC950 are described in the methods section, in Supplementary Table 1 and 
Supplementary Fig.1–5. Here, we describe how MCC950 is a highly potent 
specific NLRP3 inhibitor, which is active in vivo in multiple NLRP3-dependent 
mouse models and in ex vivo samples from individuals with CAPS.  
Results 
MCC950 inhibits both canonical and non-canonical NLRP3 activation 
The effect of MCC950 (Fig. 1a) on NLRP3 inflammasome activation was tested 
in mouse bone marrow derived macrophages (BMDM), human monocyte derived 
macrophages (HMDM) and human peripheral blood mononuclear cells (PBMC). 
Cells were first primed with LPS then pre-treated with MCC950 and lastly 
stimulated with the NLRP3 stimulus ATP. Treating cells with nanomolar 
concentrations of MCC950 dose dependently inhibited the release of IL-1β in 
BMDM (Fig. 1b), HMDM (Supplementary Fig. 6a) and PBMC (Supplementary Fig. 
6b. The half-maximal inhibitory concentration (IC50) of MCC950 in BMDM was 
approximately 7.5 nM, while in HMDM it had a similar inhibitory capacity (IC50 = 
8.1 nM). LPS-dependent tumor necrosis factor-α (TNF-α) secretion was not 
impaired by MCC950 (Fig. 1b and Supplementary Fig. 6a,b) demonstrating that 
the inhibition of IL-1β secretion was specific. 
The amount of caspase-1 p10 (an auto-processed fragment of caspase-1) was 
dose-dependently reduced in supernatants from MCC950-treated BMDM and 
PBMC (Fig. 1c and Supplementary Fig. 6c), suggesting MCC950 inhibits the 
activation of caspase-1 by NLRP3. Correspondingly, the processing of IL-1β was 
inhibited by MCC950 (Fig. 1c and Supplementary Fig. 6c). MCC950 treatment 
did not consistently affect the expression of pro-IL-1β or pro-caspase-1 in cell 
lysates (Fig. 1c and Supplementary Fig. 6c). Similarly, treatment with glyburide 
inhibited caspase-1 activation and IL-1β processing in these assays (Fig. 1c and 
Supplementary Fig. 6c).  
We also tested MCC950 with other NLRP3 stimuli. LPS primed BMDM were 
treated with MCC950 and stimulated with the ionophore nigericin20 (Fig. 1d–g) or 
monosodium urate crystals (MSU)21 (Supplementary Fig. 6d–g). MCC950 
inhibited IL-1β release in response to both stimuli (Fig. 1d and Supplementary 
Fig 6d) but did not block TNF-α secretion (Fig. 1e and Supplementary Fig. 6g). 
IL-1α and lactate dehydrogenase (LDH) release induced by nigericin were 
potently blocked by MCC950 (Fig. 1 f,g) but MCC950 did not block IL-1α or LDH 
in response to MSU (Supplementary Fig. 6e,f). It was previously demonstrated 
that MSU induced IL-1α and LDH release is NLRP3 independent22,23. The effects 
of MCC950 on IL-1α and LDH release (Fig. 1f,g and Supplementary Fig. 6e,f) 
thus suggest that MCC950 specifically blocks NLRP3-dependent pyroptotic cell 
death. In contrast to short-term stimulation with LPS (3 h), PBMC seeded at high 
density and stimulated with LPS alone for 24 h activate caspase-1 and secrete 
IL-1β due to endogenous ATP release24. We found that MCC950 also dose 
dependently inhibited IL-1β but not TNF-α secretion in this assay (Supplementary 
Fig. 6 h,i). 
Gram-negative bacteria and intracellular LPS are sensed by a non-canonical 
pathway, resulting in caspase-11-dependent pyroptotic cell death and IL-1β 
production4. NLRP3 is required for IL-1β processing by the non-canonical 
pathway25,26. We activated caspase-11 in BMDM primed with the TLR2/1 ligand 
Pam3CSK4 and transfected with LPS26 (Fig 1h–j). Using Casp11–/– and Nlrp3–/–  
BMDM we confirmed that IL-1β secretion is dependent on both NLRP3 and 
caspase-11 and that LDH and IL-1α release are not dependent on NLRP3 in this 
assay (Fig. 1h–j). We found that pre-treatment of wild-type (WT) cells with 
MCC950 prior to transfection with LPS resulted in a dose-dependent inhibition of 
IL-β release (Fig. 1h) but had no effect on IL-1α secretion (Fig. 1i) or LDH 
release (Fig. 1j). MCC950 thus specifically blocks caspase-11-directed NLRP3 
activation and IL-1β secretion upon stimulation of the non-canonical pathway.  
MCC950 does not inhibit NLRC4, AIM2, NLRP3 priming or TLR signaling  
Next we examined whether MCC950 could inhibit the activation of other 
inflammasome complexes. NLRC4-stimulated IL-1β and TNF-α secretion (as 
activated by Salmonella typhimurium27) were not inhibited by MCC950 even at a 
concentration of 10 µM (Fig. 2a). MCC950 did not inhibit caspase-1 activation or 
IL-1β processing in response to S. typhimurium (Fig. 2b). The expression of pro-
caspase-1 and pro-IL-1β in cell lysates was not substantially affected by 
MCC950 treatment (Fig. 2b). Parthenolide has previously been shown to inhibit 
NLRC4 dependent caspase-1 activation15, although it did not do so in these 
experiments (Fig. 2b). Parthenolide attenuated IL-1β and TNF-α secretion (Fig. 
2a) and also pro-IL-1β expression (Fig. 2b) suggesting its inhibitory effect is on 
the Nuclear factor-κB pathway rather than on caspase-1 activation by NLRC4.  
The effect of MCC950 on the non-NLR AIM2 inflammasome was examined by 
transfecting BMDM with the dsDNA analogue Poly(dA:dT)28-31. MCC950 
treatment did not attenuate IL-1β or TNF-α secretion from BMDM in response to 
stimulation with LPS and Poly(dA:dT) (Fig. 2c). However, IL-1β but not TNF-α 
secretion was inhibited in cells treated with a Bayer cysteinyl leukotriene receptor 
antagonist 1-(5-carboxy-2{3-[4-(3-
cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid, as has 
been previously described14 (Fig. 2c). The Bayer compound, but not MCC950, 
inhibited Poly(dA:dT) stimulated caspase-1 activation (Fig. 2d).  
We then specifically examined whether MCC950 influenced the priming phase of 
NLRP3 activation. BMDM were pre-treated with MCC950 or parthenolide and 
then stimulated with TLR ligands (Fig. 2e,f). As shown in Fig. 2e the LPS 
stimulated induction of NLRP3 and pro-IL-1β was not affected by MCC950 pre-
treatment. Likewise, MCC950 did not affect LPS- or Poly(A:U)-induced TNF-α 
secretion (Fig. 2f). In contrast parthenolide, which is an inhibitor of IκB Kinase-β 
(IKK-β)32 abrogated both TLR4- and TLR3-stimulated TNF-α production. 
Together these data demonstrate that MCC950 does not inhibit TLR signalling or 
the priming phase of NLRP3 activation. 
MCC950 blocks NLRP3 induced ASC oligomerization 
We next examined the formation of NLRP3 dependent ASC oligomers, a key 
event in NLRP3 inflammasome activation. Similar to results with ATP stimulated 
cells (Fig. 1c) MCC950 and glyburide inhibited nigericin induced caspase-1 and 
IL-1β processing (Fig. 3a) MCC950 did not alter the expression of pro-caspase-1, 
pro-IL-1β or ASC in cell lysates (Fig. 3a). Cytosolic fractions from cell lysates 
were cross-linked and ASC monomers and higher order complexes were 
observed after stimulation with LPS and nigericin. ASC-complex formation was 
attenuated by MCC950 and glyburide (Fig. 3a). ASC oligomerization was also 
observed using immortalized macrophages stably expressing cerulean 
fluorescent protein tagged ASC. Upon NLRP3 activation by ATP the cerulean-
ASC condenses into a large speck in each cell (Fig. 3b). Pre-treatment with 
MCC950 inhibited speck formation (Fig. 3b). The relatively high concentration of 
MCC950 required to block speck formation in the assay may be due to the nature 
of the cell line that also stably expresses high levels of NLRP3 and thus does not 
require priming. ASC-cerulean cells were examined using a range of 
inflammasome ligands (Fig. 3c and Supplementary Fig. 7). The number of 
activated cells observed after stimulation with nigericin or the lysosomal 
destabiliser LeuLeu-OMe which activates NLRP333 was dose dependently 
decreased by pre-treatment with MCC950. Speck formation was not decreased 
by MCC950 in cells stimulated with the NLRP1 ligand lethal toxin34 indicating the 
selectivity of MCC950 for NLRP3 (Fig. 3c and Supplementary Fig. 7).  
MCC950 does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions 
We next sought to address the mechanism of action of MCC950. K+ efflux is a 
trigger common to all NLRP3 activators35 and MCC950 is structurally related to 
sulfonylurea drugs such as glyburide that are known to target ATP-sensitive K+ 
channels36. MCC950 dose dependently inhibited IL-1β release induced by 
nigericin, ATP and SiO2 in LPS primed macrophages, but did not prevent K+ 
efflux triggered by these stimuli (Fig. 4a,b). It has been previously demonstrated 
that NLRP1 inflammasome activation is blocked by high concentrations of 
extracellular K+37 and we found that MCC950 does not block NLRP1 activation 
(Fig. 3c). These data suggest that MCC950 inhibits NLRP3 activation 
downstream of K+ efflux. 
A requirement for Ca2+ signaling in the activation of NLRP3 was previously 
demonstrated38. We examined whether MCC950 altered ATP induced Ca2+ flux 
(Fig. 4c-e). Ice–/– BMDM were tested as caspase-1 activation can lead to 
nonspecific membrane permeation and Ca2+ flux. Pre-treatment with MCC950 in 
WT or Ice–/– BMDM did not substantially affect the ATP induced increase in 
intracellular Ca2+ (Fig. 4c–e), suggesting MCC950 is unlikely to inhibit NLRP3 
activation by modulating Ca2+ flux.                                                                                      
As we had observed that MCC950 could prevent NLRP3-induced ASC 
oligomerization we next tested whether MCC950 could prevent direct NLRP3-
NLRP3 or NLRP3-ASC interactions (Fig. 4f–h). HEK293T cells were transfected 
with NLRP3 and ASC, treated with 50 µM MCC950 and then a co-
immunoprecipitation assay with NLRP3 was performed. MCC950 did not alter the 
interaction between NLRP3 with NLRP3 (Fig. 4f lanes 4 and 5) or NLRP3 with 
ASC (Fig. 4g lanes 4 and 5). We also employed a FACS based assay to analyze 
GFP–tagged ASC speck formation induced by NLRP3 expression in a ligand 
independent manner (Fig. 4h). Micromolar doses of MCC950 did not decrease 
the percentage of ASC speck containing cells. Although we cannot rule out that 
MCC950 interacts directly with NLRP3, these data suggest that it does not 
prevent inflammasome formation by directly blocking NLRP3 oligomerization or 
NLRP3-ASC interactions. 
MCC950 inhibits NLRP3 in vivo and attenuates EAE severity 
We next investigated the effects MCC950 in vivo. The induction of IL-1β by 
intraperitoneal (i.p.) injection of LPS was shown to be NLRP3 dependent39. We 
thus examined whether MCC950 could block this induction of IL-1β. Mice were 
pre-treated with MCC950 one hour before i.p. injection of LPS and were 
assessed two hours later (Fig. 5a–c). Pre-treatment with MCC950 reduced 
serum concentrations of IL-1β and IL-6 while it did not considerably decrease the 
amount of TNF-α, indicating that MCC950 is active in vivo.  
The effect of MCC950 in animal models of NLRP3 mediated diseases was then 
tested. EAE is a mouse model of the human disease MS. EAE is induced by 
immunization with a CNS auto-antigen and causes T cell mediated inflammation 
and demyelination. IL-1 signalling is crucial to the induction of IL-17 production 
from pathogenic CD4+ Th17 and γδ+ T cells40-42. More recently it has been 
demonstrated that the development of EAE requires NLRP343. We investigated 
the possibility that MCC950 may suppress T cell responses that mediate 
autoimmune disease.  Treatment of mice with MCC950 delayed the onset and 
reduced the severity of EAE (Fig. 5d). Intracellular cytokine staining and FACS 
analysis of brain mononuclear cells from mice sacrificed on day 22 showed 
modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in 
MCC950 treated mice in comparison with PBS-treated mice (Fig. 5e). IFN-γ and 
particularly IL-17 producing cell numbers were also reduced in both the CD4+ 
and γδ+ sub-populations of CD3+ T cells (Fig. 5f,g).  
MCC950 rescues a mouse model of CAPS and inhibits NLRP3 in human 
MWS cells 
A mouse model of the human CAPS disease MWS was generated by expression 
of the MWS associated mutation Nlrp3A350VneoR (corresponding to NLRP3A352V 
in humans) specifically in the myeloid lineage (crossed with LysMCre)44. MWS 
mice die in the neonatal period and have increased concentrations of circulating 
IL-1β and IL-1844. We treated MWS mice with MCC950 (Fig. 6a) and observed 
that they had increased body weight at day 9 compared to PBS treated controls 
(Fig. 6a and 6b). MCC950 also increased survival up to day 38–45 even after 
treatment was stopped at day 28 (Fig. 6c,d). MCC950 treatment also decreased 
the concentration of circulating IL-18 in MWS mice; however, IL-18 then 
increased after the withdrawal of MCC950 (Fig. 6e). A mouse strain containing 
an Nlrp1 activating mutation (Nlrp1aQ593P) also displays increased concentrations 
of serum IL-18 relative to WT controls45. However, treatment of NLRP1 mutant 
mice with MCC950 did not significantly alter serum concentrations of IL-18 (Fig. 
6e) (P = 0.7). These data clearly demonstrate that MCC950 effectively and 
specifically blocks NLRP3 activation in vivo. 
Finally we tested the effects of MCC950 in PBMC from individuals with MWS, a 
CAPS caused by gain of function mutations in NLRP346. PBMC from individuals 
with MWS secrete IL-1β in response to LPS alone without an NLRP3 
stimulus47,48. When PBMC from an individual with MWS were stimulated with 
LPS, caspase-1 and IL-1β processing were detected in the cell supernatants (Fig. 
6f). However, when pre-treated with MCC950 both IL-1β and caspase-1 
processing were dose dependently inhibited (Fig. 6f). MCC950 treatment did not 
alter the expression of pro-IL-1β or pro-caspase-1 (Fig. 6f). Samples from four 
more individuals with MWS were also found to be sensitive to MCC950 inhibition 
(Supplementary Fig. 8). Thus, MCC950 inhibits inflammasome activation in 
samples from individuals with CAPS. 
In vitro and in vivo pharmacokinetics of MCC950 
To assess the therapeutic potential of MCC950, the pharmacokinetic profile 
of this compound was examined in a number of in vitro absorption, 
distribution, metabolism and excretion assays. The stability of MCC950 when 
incubated with human or mouse liver microsomes was good with more than 
70% of the compound remaining after 60 min (Supplementary Table 2). The 
drug-drug interaction potential of MCC950 was also tested (Supplementary 
Table 3,4). MCC950 was incubated at a single concentration of 10 μM with 
human liver microsomes and a cocktail of standard substrates specific for 
each of the 5 major cytochrome P450 (CYP) isozymes (1A2, 2C9, 2C19, 2D6 
and 3A4). The inhibition of the 5 major CYP enzymes with MCC950 was low 
at less than 15% (Supplementary Table 4). In order to explore any potential 
for cardiotoxicity, the effect of MCC950 on the human ether-a-go-go (hERG) 
potassium channel was examined using the high throughput automated patch 
clamp method (QPatchHTX) (Supplementary Table 5). In this assay the IC50 
for hERG was greater than 30 μM suggesting MCC950 has >3,000 fold 
selectivity window (IC50 for NLRP3 = <10 nM). Finally, a single dose 
pharmacokinetic profile of MCC950 in C57Bl/6 mice was determined via 
intravenous (3 mg/kg) and oral (20 mg/kg) administration (Supplementary Fig. 
9). The area under the curve was 163,410 ng.h/mL with a Cmax of 25,333 
ng/mL and half-life of 3.27 hours. The oral bioavailability of MCC950 was 
68%.  
Discussion  
We describe here MCC950, a potent selective NLRP3 inhibitor that is active both 
in mice in vivo and in human cells ex vivo. MCC950 may be a useful tool to 
explore NLRP3 biology and druggability.  
We have characterised the mechanism of action of MCC950 within our current 
understanding of NLRP3 activation. MCC950 did not block K+ efflux, Ca2+ flux or 
ligand independent direct NLRP3 and ASC interactions. Reactive oxygen species 
(ROS) have been implicated but current evidence suggests that ROS are not 
involved in NLRP3 activation by nigericin or ATP38,49, which are both potently 
inhibited by MCC950. As MCC950 is active against the hypersensitive NLRP3 
mutations in MWS, against non-canonical NLRP3 activation and against all 
tested canonical NLRP3 stimuli this suggests that its molecular target of MCC950 
is NLRP3 itself or is closely linked to the activation of NLRP3. It is possible that 
MCC950 binds to NLRP3 and affects a key step in its activation that might 
involve post-translational modification. Future work will aim to define the precise 
mechanism of action of MCC950. 
We note that targeting NLRP3 might present certain advantages over biologic 
inhibitors of IL-1β. MCC950 had a dramatic effect on a genetic mouse model of 
CAPS. The rescue afforded by MCC950 is far more substantial than the targeted 
blockade of IL-1β alone, which does not prevent lethality44. Some of the 
pathology of this disease may be due to IL-18 and pyroptosis50, which MCC950 
will block. IL-1β maturation can be mediated by a number of different enzymes 
including serine proteases and caspase-83 and we have demonstrated that 
MCC950 does not block the major anti-microbial inflammasomes NLRC4 and 
NLRP1. Thus, specific targeting of NLRP3 will not result in the complete 
blockade of IL-1β in vivo during infection and antimicrobial responses may 
remain intact. MCC950 may therefore have less immunosuppressive effects 
when compared to biologics such as Canakinumab, which has been shown 
clinically to increase the risk of these serious infections12,51. MCC950 will also 
have a shorter half-life compared to the biologics Canakinumab and Rilonacept, 
and can therefore be withdrawn should unwanted effects occur such as 
infections. A small molecule such as MCC950 may also be more cost effective 
than biologic agents52. The future clinical development of MCC950 or derivatives 
may result in the development of new anti-inflammatory therapies for CAPS, but 
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Figure legends 
Figure 1. MCC950 inhibits NLRP3 inflammasome activation in response to 
canonical and non-canonical NLRP3 stimuli.                                             
(a) MCC950 structure. (b) Production of IL-1β and TNF-α from BMDM stimulated 
with LPS and ATP and treated with MCC950 (1–1,000 nM) measured by ELISA. 
Cytokine level is normalized to DMSO control treated cells. Data are expressed 
as mean ± S.E.M. of six independent experiments carried out in triplicate. Non-
linear regression analysis was performed and Log [M] MCC950 vs. normalized 
response (variable slope) curve is presented. (c) Western blots of cell lysates 
and supernatants from BMDM stimulated with LPS and ATP and treated with 
MCC950 or glyburide. These results are representative of five independent 
experiments. (d–g) Production of IL-1β, TNF-α, IL-1α and LDH from BMDM 
stimulated with LPS and nigericin and treated with MCC950 as measured by 
ELISA (d–f) and LDH assay (g). Data are expressed as mean ± S.E.M. of three 
independent experiments carried out in triplicate. (h–j) Production of IL-1β, IL-1α 
and LDH from BMDM from the indicated genotypes stimulated with Pam3CSK4 
and transfected LPS and treated with MCC950 as measured by ELISA (h,i) and 
LDH assay (j). Data are expressed as mean ± S.E.M. of three (Nlrp3–/–), four 
(casp11–/–) or six (C57BL/6) independent experiments. 
Figure 2. MCC950 does not inhibit NLRC4, AIM2, TLR signalling or priming 
of NLRP3. 
(a) Production of IL-1β and TNF-α from BMDM stimulated with LPS and S. 
typhimurium and treated with MCC950 and parthenolide measured by ELISA. 
Cytokine level is normalized to DMSO control treated cells. Data are expressed 
as mean ± S.E.M. of four independent experiments carried out in triplicate. (b) 
Western blots of cell lysates and supernatants from BMDM stimulated with LPS 
and S. typhimurium and treated with MCC950 and parthenolide. These results 
are representative of four independent experiments. (c) Production of IL-1β and 
TNF-α from BMDM stimulated with LPS and transfected Poly(dA:dT) and treated 
with MCC950 and Bayer compound measured by ELISA. Cytokine level is 
normalized to DMSO control treated cells. Data are expressed as mean ± S.E.M. 
of five independent experiments carried out in triplicate. (d) Western blots of cell 
lysates and supernatants from BMDM stimulated with LPS and transfected 
Poly(dA:dT) and treated with MCC950 and Bayer compound. These results are 
representative of two independent experiments. (e) Western blots of cell lysates 
from BMDM treated with MCC950 and stimulated with LPS (4 h). These results 
are representative of three independent experiments. (f) Production of TNF-α 
from BMDM treated with MCC950 and parthenolide and stimulated with LPS or 
Poly(A:U) measured by ELISA. Data shown represent mean cytokine level ± S.D. 
from triplicate determinations and are representative of three independent 
experiments. 
Figure 3. MCC950 blocks NLRP3 dependent ASC oligomerization  
(a) Western blots of cell lysates, supernatants and cross-linked cytosolic pellets 
from BMDM stimulated with LPS and nigericin and treated with MCC950 and 
parthenolide. These results are representative of three independent experiments. 
(b) Live cell imaging of ASC-cerulean cells treated with MCC950 and stimulated 
with ATP. At least five different images were taken of each condition at an 
original magnification of ×40. Results are representative of three independent 
experiments. (c) The percentage of ASC-cerulean cells containing an ASC speck 
after treatment with MCC950 (0.05–10 µM) and stimulation with nigericin, 
LeuLeu-Ome or lethal toxin. Data shown represent the mean ± S.D. from 
triplicate measurements. 
Figure 4. MCC950 does not block K+ efflux, Ca2+ flux or direct NLRP3 and 
ASC interactions.  
(a) The relative level of intracellular K+ determined by ICP-OES in Nlrp3–/– BMDM 
stimulated with LPS and nigericin, ATP and SiO2 and treated with MCC950. (b) 
IL-1β production from C57BL/6 BMDM stimulated with LPS and nigericin, ATP 
and SiO2 measured by ELISA. (a–b) Data are presented as mean ± S.D. from 
triplicate measurements and are representative of three independent 
experiments. (c) A trace showing ATP induced Ca2+ flux was measured using the 
FLIPRTETRA system in C57BL/6 BMDM stimulated with LPS and treated with 
MCC950. The results are representative of three independent experiments. (d,e) 
The relative response to ATP induced Ca2+ flux in C57BL/6 (d) and Ice–/– (e) 
BMDM stimulated with LPS and treated with MCC950 as measured using the 
FLIPRTETRA system. Data are presented as mean ± S.E.M. and are 
representative of three independent experiments. (f,g) Western blots of cell 
lysates and FLAG-immunoprecipitation samples from HEK-293T cells transfected 
with FLAG-NLRP3, HA-NLRP3, ASC or empty vector plasmids as indicated and 
treated with MCC950. These results presented are representative of three 
independent experiments. (h) The percentage of ASC speck containing live HEK-
293T cells transfected with GFP-ASC and NLRP3-mCherry plasmids as 
indicated, treated with MCC950. and analysed by FACS. Data is presented as 
mean ± S.E.M. from three independent experiments each carried out in triplicate.  
Figure 5. MCC950 is active in vivo and treatment of mice with MCC950 
attenuates EAE  
(a–c) Serum levels of IL-1β (a), TNF-α (b) and IL-6 (c) measured by ELISA from 
C57BL/6 mice pre-treated with MCC950 or vehicle control, 2 h post i.p. LPS 
injection. Data shown are mean values ± S.D. n=3, *P ≤ 0.05 by Mann-Whitney 
test. (d) Clinical scores after EAE induction from C57BL/6 treated with PBS or 
MCC950. Mean ± S.D. n=6.(e–g) Representative dot plots from five mice and 
mean percentages ± S.D. of live IL-17 and IFN-γ secreting CD3+ T cells (e), 
CD3+ CD4+ T cells (f) or CD3+ γδ TCR+ cells (g) from brain mononuclear cells 
isolated on day 22 post EAE induction in C57BL/6 mice treated with PBS or 
MCC950 are shown. n=5, *P ≤ 0.05 by Mann-Whitney test. 
Figure 6. MCC950 inhibits NLRP3 activation in a mouse model of MWS and 
in MWS PBMC ex vivo                                                                         
(a) Nlrp3A350VneoR crossed with LysMCre mice (NLRP3 mutant) treated with PBS 
or MCC950 at day 9. (b) Weight at day 9. Mean ± S.D. WT PBS and WT 
MCC950 both n=4, NLRP3 mutant PBS n=3 and NLRP3 mutant MCC950 n=6. 
**P ≤ 0.005 by unpaired two-tailed t-test. (c) Survival of NLRP3 mutant mice 
treated with PBS or MCC950 up to day 45 (MCC950 withdrawn at day 28). 
MCC950 group n=5, PBS group n=9. (d) WT and NLRP3 mutant mice on day 17. 
(e) Plasma IL-18 concentrations as measured by ELISA at day 9, and again for 
NLRP3 mutant mice 14 days after drug withdrawal. WT PBS and WT MCC950 
both n=4, NLRP3 mutant PBS n=5 and NLRP3 mutant MCC950 and withdrawal 
both n=4. NLRP1aQ593P  mice (NLRP1 mutant) PBS and MCC950 both n=3.  
Data shown are mean ± S.D. * P ≤ 0.05 by Mann-Whitney test. (f) Western blots 
of cell lysates and supernatants from PBMC isolated from an individual with 
MWS (mutation E313K) stimulated with LPS and treated with MCC950. 
Methods 
MCC950 synthesis and formulation 
MCC950 was synthesised via a 10 step route53. The 1,2,3,5,6,7-hexahydro-s-
indacen-4-amine moiety was synthesised from 2,3-dihydro-1H-indene where 
Friedel-Craft’s acylation using 3-chloropropionyl chloride and aluminium 
trichloride in dichloromethane gave 3-chloro-1-(2,3-dihydro-1H-inden-5-
yl)propan-1-one which was not purified but used directly in the cyclisation 
reaction. Cyclisation was achieved by heating the crude product to 60 °C in 
concentrated sulphuric acid for 72 h then the solution was cooled to 0 °C and 
nitrated directly using a 1:1 mixture of nitric and sulphuric acids. After trituration 
with ice cold methanol a regio-isomeric mixture of 4-nitro and 8-nitro-3,5,6,7-
tetrahydro-s-indacen-1(2H)-one was isolated in 61% yield over the three 
synthetic steps. Simultaneous reduction of the ketone and nitro groups was 
successfully achieved by hydrogenation in methanol over Pearlman’s catalyst in 
the presence of methanesulfonic acid in 62% yield after purification by column 
chromatography on silica. 
The required 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide moiety was 
synthesised from ethyl furan-3-carboxylate. Sulfonylation of the furan 5 position 
was readily achieved using chlorosulfonic acid in dichloromethane at –10 °C to 
room temperature. The 4-(ethoxycarbonyl)furan-2-sulfonic acid intermediate was 
not isolated but chlorinated directly by addition of pyridine then phosphorous 
pentachloride to the reaction mixture. After work-up and silica column 
chromatography ethyl 5-(chlorosulfonyl)furan-3-carboxylate was isolated in 56% 
yield over the two steps. The chloride was displaced using ammonium 
bicarbonate in water and acetone to yield 4-(2-hydroxypropan-2-yl)furan-2- 
sulfonamide in 59% yield after aqueous work-up. The sulphonamide was pure 
enough to use in the next reaction step where the ester moiety was reduced, 
using methylmagnesium chloride in tetrahydrofuran, to the tertiary alcohol giving 
4-(2-hydroxypropan-2-yl)furan-2-sulfonamide in 53% yield. 
 
To complete the synthesis of MCC950 the 1,2,3,5,6,7-hexahydro-s-indacen-4-
amine was converted to the corresponding isocyanate by reaction with di-
tbutyldicarbonate and N,N-dimethylaminopyridine in acetonitrile. The sodium salt 
of 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide was prepared by reaction with 
freshly prepared sodium methoxide solution and the solvent removed in vacuo to 
give a hygroscopic sodium salt. The salt was suspended in acetonitrile, the 
preformed isocyanate solution added and the reaction stirred overnight. MCC950 
sodium salt was filtered directly from the reaction mixture and the beige solid was 
triturated using ethyl acetate. The product was dissolved in water, treated with 
activated charcoal and filtered through celite. The aqueous solution was freeze 
dried to give the desired product as the sodium salt. 
 
Spectra of MCC950 and intermediates are consistent with literature precedent53 
and HRMS (ESI) calculated for MCC950 C20H23N2O5S (M-H+) 403.1333, 
found 403.1351. MCC950 sodium salt is highly soluble in aqueous solutions and 
therefore was formulated in saline for in vivo studies. 
 
Cell culture                                                                                                      
Bone marrow from C57BL/6, Nlrp3–/– (Martinon et al.21), Ice–/– (Kuida et al.54 and 
Casp11–/– (Wang et al.55_ENREF_54) mice was differentiated for 7 days in DMEM 
supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin (P/S) 
and 20% L929 mouse fibroblast supernatant or in RPMI 1640 medium 
supplemented with 10% FCS, 1% P/S and 10 ng/ml human M-CSF 
(ImmunoTools). Stably transfected ASC-cerulean macrophages as described by 
Hett et al.56_ENREF_55 were a kind gift from Dr. Eicke Latz, University of Bonn, 
Germany, and were cultured in DMEM supplemented with 10% FCS and 1% P/S. 
HEK293T cells were cultured in DMEM supplemented with 10% FCS and 1% 
P/S. Blood specimens from individuals with CAPS were drawn after obtaining 
informed consent under a protocol approved by the NIAMS/NIDDK Institutional 
Review Board. Human PBMC were isolated by LSM-Lymphocyte Separation 
Medium (50494, MP Biomedicals) from freshly drawn peripheral venous blood. 
PBMC were cultured in RPMI 1640 medium containing 10% FCS and antibiotics. 
HMDM were generated from CD14+ monocytes by differentiation for 7 days in 
IMDM supplemented with 10% FCS, 1% P/S and 10 ng/ml human M-CSF 
(Miltenyl Biotec) as described by Croker et al_ENREF_56.57 
Inflammasome activation assays                                                               
BMDM were seeded at 5 × 105/ml or 1 × 106/ml, HMDM at 5 × 105/ml and PBMC 
at 2 × 106/ml or 5 × 106/ml in 96 well plates. The following day the overnight 
medium was replaced and cells were stimulated with 10 ng/ml LPS from 
Escherichia coli serotype EH100 (ra) TLRgrade™ (Alexis Biochemicals) for 3 h. 
Medium was removed and replaced with serum free medium (SFM) containing 
DMSO (1:1,000), MCC950 (0.001–10 µM), glyburide (200 µM) (Sigma Aldrich), 
parthenolide (10 µM) (Enzo Life Sciences) or Bayer cysteinyl leukotriene receptor 
antagonist 1-(5-carboxy-2{3-[4-(3-
cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 µM) 
(Amgen Inc., Thousand Oaks, CA, USA) for 30 min. Cells were then stimulated 
with inflammasome activators: 5 mM adenosine 5’-triphosphate disodium salt 
hydrate (ATP) (1 h), 1 µg/ml Poly(deoxyadenylic-thymidylic) acid sodium salt 
(Poly dA:dT) (Sigma Aldrich) transfected with Lipofectamine 2000™ (Invitrogen) 
(3–4 h), 200 µg/ml MSU (overnight) and 10 µM nigericin (Invivogen) (1 h) or S. 
typhimurium UK-1 strain (M.O.I. 20) obtained from Dr. Sinead Corr, Trinity 
College Dublin, Ireland (2 h). Cells were also stimulated with 25 µg/ml 
Polyadenylic–polyuridylic acid (Invivogen) (4 h). For non-canonical 
inflammasome activation cells were primed with 100 ng/ml Pam3CSK4 
(Invivogen) for 4 h, medium was removed and replaced with SFM containing 
DMSO or MCC950 and 2 µg/ml LPS was transfected using 0.25% FuGENE® 
(Promega) for 16 h. Supernatants were removed and analysed using ELISA kits 
according to the manufacturer’s instructions (DuoSet® R&D Systems or 
ReadySetGo!® eBioscience). LDH release was measured using the CytoTox96® 
non-radioactive cytotoxicity assay (Promega) 
Western blotting                                                                                                   
Cell lysates were prepared by direct lysis in 50 μl 5× Laemmli sample buffer. 
The protein content of supernatants was concentrated using StrataClean™ resin 
(Agilent Technologies) according to the manufacturer’s instructions. The protein 
samples were resolved on 15% SDS-PAGE gels and transferred onto 
polyvinylidene diflouride (PVDF) membrane using a wet transfer system. 
Membranes were blocked in 5% (w/v) dried milk in TBS-T (50 mM Tris/HCL, pH 
7.6, 150 mM NaCl and 0.1% (v/v) Tween-20) for 1 h at room temperature (RT). 
Membranes were incubated with primary antibody diluted in 5% (w/v) dried milk 
in TBS-T, followed by incubation with the appropriate horseradish peroxidise 
(HRP) conjugated secondary antibody diluted in 5% (w/v) dried milk in TBS-T for 
1 h. Membranes were developed using 20× LumiGLO® chemilluminescent 
reagent (Cell Signaling Technology). Membranes were stripped using Restore™ 
PLUS western blot stripping buffer (Thermo Fisher Scientific) before being 
reprobed.  
PBMC from individuals with CAPS were seeded at 2 × 106/ml in 12 well plates 
and then primed with 1 µg/ml LPS for 3 h. Medium was replaced with SFM 
containing MCC950 (5–1,000 nM). After 45 min, cell culture supernatants and 
cell lysates were collected. Samples were resolved using Novex® Tris-Glycine 
Gel Systems (Invitrogen).   
Primary antibodies used were: ASC antibody (AL177) (1 in 1,000) (Enzo Life 
Sciences), β-actin (AC-74) (1:10,000), FLAG M2 (F1804) (1:2,500) and α-Tubulin 
clone B-5-1-2 (T5168) (1:5,000) (Sigma Aldrich), Mouse caspase-1 p10 (sc-514) 
(1:1,000), human caspase-1 p10 (sc-515) (1:1,000), human pro-caspase-1 (sc-
622) (1:1,000) and human actin (sc-1615) (1:1,000) (Santa Cruz Biotechnology), 
mouse IL-1β (AB-401-NA) (1:1,000) and human IL-1β (AF-201-NA) (1:1,000) 
(R&D Systems), HA.11 clone 16B12 (MMS-101R) (1:2,000) (Covance), NLRP3 
clone Cryo-2 (AG-20B-0014) (1:1,000) (Adipogen). Secondary HRP conjugated 
antibodies were: anti-mouse IgG, anti-rabbit IgG and anti-goat IgG (all 1:1,000) 
(Jackson ImmunoResearch Inc.).  
ASC complex isolation                                                                                    
BMDM were seeded at 106/ml in 6 well plates. The following day medium was 
replaced and cells were stimulated with 10 ng/ml LPS for 3 h. Medium was 
removed and replaced with SFM containing the indicated inhibitors or controls for 
30 min, followed by the addition of 10 μM nigericin for 1 h. The supernatants 
were removed, cells were rinsed in ice-cold PBS and 500 μl ice-cold buffer (20 
mM Hepes-KOH, pH 7.5, 150 mM KCL, 1%NP-40 0.1 mM PMSF, 1 mg/ml 
leupeptin, 11.5 mg/ml aprotinin and 1 mM sodium orthovanadate) was added. 
Cells were scraped and lysed by shearing 10× through a 21 gauge needle. 50 μl 
of lysate was removed for Western blot analysis. Lysates were centrifuged at 330 × g for 10 min at 4 °C. The pellets were washed twice in 1 ml ice-cold PBS and 
resuspended in 500 μl PBS. 2 mM disuccinimydyl suberate (from a fresh 100 mM 
stock prepared from DSS equilibrated to RT and made up in dry DMSO) was 
added to the re-suspended pellets, which were incubated at RT for 30 min with 
rotation. Samples were then centrifuged at 330 × g for 10 min at 4 °C. The 
supernatant was removed and the cross-linked pellets were resuspended in 30 μl 
Laemmli sample buffer. Samples were boiled for 5 min at 99 °C and analysed by 
Western blotting. 
Confocal microscopy                                                                                        
For confocal images ASC-cerulean cells were seeded at 2 × 105/ml the day prior 
to use in experiments on 35 mm glass bottom culture dishes. The following day 
the overnight medium was replaced with SFM containing the indicated inhibitors 
or controls for 30 min. Cells were then stimulated with 5 mM ATP for 30 min. 
Imaging was performed on an Olympus FluoView™ FV1000 Microscope 
equipped with a temperature and CO2 controlled chamber. For quantification of 
ASC speck formation ASC-cerulean cells were seeded at 3.75 × 105/ml the day 
prior to use in experiments in 384 well plates. The following day MCC950 was 
added using a HP compound printer, 1 h later activators were added: 10 μM 
nigericin (1.5 h), 1 mM LeuLeuOMe (2 h) and 1 μg/ml lethal toxin (1 μg/ml lethal 
factor plus 1 μg/ml protective antigen - 2 h). A solution of DRAQ5 (1:1,000) and 
1% formaldehyde were added and the plates were quantitated as described in 
Hett et al56._ENREF_61 
K+ analysis                                                                                                                          
Intracellular K+ measurements were performed by inductively coupled plasma 
optical emission spectrometry (ICP-OES) with a PerkinElmer Optima 2000 DV 
spectrometer using yttrium as internal standard as described by Mũnoz-Planillo 
et al.35 Cells were stimulated with 500 ng/ml LPS for 3 h, treated with MCC950 
(10–300 nM) and then stimulated with 10 µM nigericin or 5 mM ATP for 30 min or 
375 µg/ml SiO2 for 6 h _ENREF_57 
Fluorescent Imaging Plate Reader (FLIPR) Ca2+ analysis                               
BMDM (3 × 104/well) were loaded for 30 min at 37 °C with a no wash calcium dye 
(Molecular Devices) in physiological salt solution (PSS; composition NaCl 140 
mM, glucose 11.5 mM, KCl 5.9 mM, MgCl2 1.4 mM, NaH2PO4 1.2 mM, NaHCO3 
5 mM, CaCl2 1.8 mM, HEPES 10 mM) containing 0.1% BSA. Cells were then 
transferred to the FLIPRTETRA (Molecular Devices) fluorescent plate reader and 
Ca2+ responses measured using a cooled CCD camera with excitation at 470–
495 nM and emission at 515–575 nM. Camera gain and intensity were adjusted 
for each plate to yield a minimum of 1,000 arbitrary fluorescence units (AFU) 
baseline fluorescence. Prior to addition of MCC950, 10 baseline fluorescence 
readings were taken, followed by fluorescent readings every second for 300 
seconds following sample addition and a further 300 seconds following addition 
of either PSS or ATP (500 µM). 
Co-immunoprecipitation assay                                                               
HEK293T cells (3 × 105 /ml) were transfected in 10 cm2 dishes by calcium 
phosphate method with the following plasmids: pEF6 mouse NLRP3 N-HA, pEF6 
mouse ASC, pEF6 mouse NLRP3 N-FLAG or empty vector control. 24 h post 
transfection cells were lysed in RIPA buffer (50 mM Tris-HCL pH8, 150 mM 
NaCL, 1 mM EDTA, 10% Glycerol, 1% Triton X-100, 1% Sodium deoxycholate, 
0.1% SDS and protease inhibitors) and disrupted by passage through a 27G 
needle. Lysates were precleared with 5 µl protein G Dynabeads (Life 
Techonologies) for 30 min at 4°C. Dynabeads were blocked in 0.5% BSA for 1 h 
at 4°C. Lysates were incubated for 1 h with 0.5 µg anti-FLAGM2 (F1804) (Sigma-
Aldrich) antibody before addition of 20 µl blocked Dynabeads for a further 2 h at 
4°C. Dynabeads captured using a magnet, washed and resuspended in 60 µl 
sample buffer and boiled for 5 min before analysis by Western blotting.  
Time of Flight Imflammasome Evaluation (TOFIE) assay                          
HEK293T cells (4 × 105 /ml) were transfected in 24 well plates using 
Lipofectamine 2000™ (Invitrogen) with the following plasmids: pEF6 human 
ASC-GFP, pEF6 human C-mCherry or empty vector control. 1 h post transfection 
cells were treated with DMSO or MCC950 (0.1–50 µM). 15 h post transfection 
cells were removed and suspended in DPBS containing 1% FCS and 2 mM 
EDTA. Cells were analysed using a Gallios™ flow cytometer (Beckman Coulter) 
and using FlowJo software. Live cells were gated on GFP and Cherry expression 
(when co-transfected). The percentage of ASC speck containing cells was 
determined by analysing the height and width of the GFP pulse area (low 
width:area and high height:area). This analysis is described in detail in by Sester 
et al.58_ENREF_62  
In vivo LPS challenge                                                                                  
C57BL/6 mice were injected intraperitoneally (i.p.) with 50 mg/kg MCC950 or 
vehicle control (DMSO/PBS) 1 h h before i.p. injection of 10 mg/kg LPS 
Escherichia coli 055:B5 (Sigma Aldrich) or PBS. After for 2 h mice were 
sacrificed and serum levels of IL-1β, TNF-α and IL-6 were measured by ELISA.     
Induction and Assessment of EAE                                                            
C57BL/6 mice were immunized subcutaneously with 150 µg of MOG peptide 35-
55 (GenScript) emulsified in CFA containing 4 mg/ml (0.4.mg/mouse) of heat-
killed MTB (Chondrex).  Mice were injected i.p. with 500 ng pertussis toxin (PT: 
kaketsuken) on days 0 and 2.  MCC950 was administered i.p. to mice (10 mg/kg) 
at induction of the disease, day 0, 1 and 2 and every 2 days thereafter.  Control 
mice were administered vehicle (PBS) at the same time points.  Mice were 
observed for clinical signs of disease daily (unblinded).  Disease severity was 
scored as follows: no clinical signs, 0; limp tail, 1; ataxic gait, 2; hind limb 
weakness, 3; hind limb paralysis, 4; and tetra paralysis, 5., Experiments were 
performed under license (BI00/2412) from The Irish Medicine Board and with 
approval from the Trinity College Dublin BioResources Ethics Committee. 
FACS analysis of EAE                                                                                                     
On day 22 post immunization mononuclear cells were isolated from whole brains 
of perfused mice with EAE, following homogenisation and centrifugation on a 
Percoll gradient. Mononuclear cells (MNC) (2 × 106/ml) were stimulated for 4 h 
with PMA (10 ng/ml) and ionomycin (1 μg/ml) in the presence of brefeldin A (5 
μg/ml). Cells were washed in PBS and re-suspended in 50 μL PBS with 1:1,000 
LIVE/DEAD® Fixable Aqua Dead Cell Stain kit (Life Technologies) for 20 min. 
Surface stains for CD3 (145-2c11) (0.5 µl/106 cells), CD4 (RM4-5) (0.5 µl/106 
cells) and γδ TCR (GL3) (1 µl/106 cells) (eBioscience) were added and cells were 
incubated for a further 20 mins. Cells were then fixed with 2% paraformaldehyde 
and washed in PBS twice, before being intracellularly stained for IL-17 or IFN-γ in 
permeabilization buffer (0.2% saponin in PBS + 1% FBS). Flow cytometric 
analysis of MNC was performed using a BD LSRFortessaTM (BD Biosciences) 
and analysed with FlowJo software. MNC were first gated on live CD3+ T cells 
followed by CD4 expression, γδ TCR expression or cytokine production.  
NLRP3 and NLRP1 activating mutation mice                                                
Mice were backcrossed to C57BL/6 at least ten times. Nlrp3A350VneoR mice 
were provided by Hal M. Hoffman, The University of California, San Diego, 
U.S.A.44 and crossed with LysMCre mice (B6.129P2-Lyz2tm1(cre)Ifo/J. MCC950 was 
administered i.p. (20 mg/kg) every second day starting at day 4 after birth. Mice 
with an activating mutation in NLRP1, Nlrp1aQ593P were generated on a C57BL/6 
background as described previously45 and administered MCC950 i.p. (20 mg/kg) 
every second day for 9 days. Blood was collected at the timepoints indicated for 
analysis of plasma cytokines by ELISA. IL-18 ELISA was performed as described 
by Westwell-Roper et al.59 Experiments were performed under AEC Project 
2013.011 and were approved by the Animal Ethics Committee of The Walter and 
Eliza Hall Institute of Medical Research. 
Statistical analyses                                                                                                   
Data are presented as average values ± S.E.M. from multiple individual 
experiments each carried out in triplicate or as average values ± S.D. from 
triplicate measurements in a representative experiment. Non-linear 
regression analysis of inhibitor vs. normalized response (variable slope) 
was performed using Prism Software (GraphPad). Statistical analysis was 
carried out using a nonparametric Mann-Whitney t test or an unpaired two-
tailed [AU: all tests were Mann Whitney? Was normality tested?] t test 
using Prism Software (GraphPad). Data were were considered to be 
significant when p ≤ 0.05 (*) or ≤ 0.005.   
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